Skip to main content

Advertisement

Table 3 Cost-utility ratio per case in 6 scenarios over 36 months post-infection

From: Efficacy and cost-effectiveness of early antiretroviral therapy and partners’ pre-exposure prophylaxis among men who have sex with men in Shenyang, China: a prospective cohort and costing study

ScenarioCost ($)Averted HIV infectionQALYCUR
Scenarios based on observed data
 Non-ART3,540NANANA
 Standard-ART6,0630.090.2128,272
 Early-ART10,0240.340.7812,864
Scenarios based on observed and hypothetical data
 Non-ART plus partners’ PrEP40,9740.380.8747,321
 Standard-ART plus partners’ PrEP33,9730.390.8938,287
 Early-ART plus partners’ PrEP15,8720.410.9416,817
  1. $ U.S. dollars, QALY quality-adjusted life-years, CUR cost-utility ratio, ART antiretroviral therapy, NA not applicable, PrEP pre-exposure prophylaxis